+ Watch BIOD
on My Watchlist
A specialty pharmaceutical company, which focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.
BIOD has quietly developed an improved mixed insulin product compatible with Lantus, which would allow the “holy grail” combination fast-acting/long acting insulin to be created. They are a top pick with an FDA review date of October 30th. Price estimate by that date of $7.00-$7.50. Once approved their insulin drug would revolutionize treatment of diabetes and will be targeting a massive market. Clinical tests and trials look good, overall very good outlook.
I tend to agree, this is the next big pharma play since ARNA. It should have better performance
I beliveve Linjeta will be approved on Oct 30th.I believe that BIOD will probably trade higher into the event.Any investor considering a position should read this article:http://seekingalpha.com/article/225291-biodel-s-linjeta-should-overcome-the-usual-fda-approval-hurdles,and consider the India data before investing.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions